These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 37952790)

  • 21. Implantable cardiac defibrillators for people with non-ischaemic cardiomyopathy.
    El Moheb M; Nicolas J; Khamis AM; Iskandarani G; Akl EA; Refaat M
    Cochrane Database Syst Rev; 2018 Dec; 12(12):CD012738. PubMed ID: 30537022
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An implantable cardioverter-defibrillator for primary prevention in non-ischemic cardiomyopathy: A systematic review and meta-analysis.
    Wasiak M; Tajstra M; Kosior D; Gąsior M
    Cardiol J; 2023; 30(1):117-124. PubMed ID: 33843044
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sudden death mechanisms in nonischemic cardiomyopathies: Insights gleaned from clinical implantable cardioverter-defibrillator trials.
    Steinberg BA; Mulpuru SK; Fang JC; Gersh BJ
    Heart Rhythm; 2017 Dec; 14(12):1839-1848. PubMed ID: 28919378
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The prognostic role of late gadolinium enhancement on cardiac magnetic resonance in patients with nonischemic cardiomyopathy and reduced ejection fraction, implanted with cardioverter defibrillators for primary prevention. A systematic review and meta-analysis.
    Anagnostopoulos I; Kousta M; Kossyvakis C; Lakka E; Paraskevaidis NT; Schizas N; Alexopoulos N; Deftereos S; Giannopoulos G
    J Interv Card Electrophysiol; 2022 Apr; 63(3):523-530. PubMed ID: 34218421
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Non-ischaemic cardiomyopathy, sudden death and implantable defibrillators: a review and meta-analysis.
    Beggs SAS; Jhund PS; Jackson CE; McMurray JJV; Gardner RS
    Heart; 2018 Jan; 104(2):144-150. PubMed ID: 28986406
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Primary prevention implantable cardioverter-defibrillator and opportunities for sudden cardiac death risk assessment in non-ischaemic cardiomyopathy.
    Pathak RK; Sanders P; Deo R
    Eur Heart J; 2018 Aug; 39(31):2859-2866. PubMed ID: 30020440
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mortality Effect of ICD in Primary Prevention of Nonischemic Cardiomyopathy: A Meta-Analysis of Randomized Controlled Trials.
    Luni FK; Singh H; Khan AR; Malik SA; Khawaja O; Riaz H; Lee W; Kabour A; Richards M; Aasbo J
    J Cardiovasc Electrophysiol; 2017 May; 28(5):538-543. PubMed ID: 28370885
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Positron emission tomography absolute stress myocardial blood flow for risk stratification in nonischemic cardiomyopathy.
    Middour TG; Rosenthal TM; Abi-Samra FM; Bernard ML; Khatib S; Polin GM; Rogers PA; Bober RM; Morin DP
    J Cardiovasc Electrophysiol; 2020 May; 31(5):1137-1146. PubMed ID: 32064730
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sudden cardiac death in nonischemic cardiomyopathy: Refining risk assessment.
    Zipse MM; Tzou WS
    J Cardiovasc Electrophysiol; 2017 Nov; 28(11):1361-1366. PubMed ID: 28670752
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Implantable cardioverter defibrillator in non-ischemic cardiomyopathy: a meta-analysis of randomized controlled trials.
    Masri A; Hammadah M; Adelstein E; Jain S; Saba S
    Cardiovasc Diagn Ther; 2017 Aug; 7(4):397-404. PubMed ID: 28890876
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Arrhythmia and Survival Outcomes Among Black Patients and White Patients With a Primary Prevention Defibrillator.
    Younis A; Ali S; Hsich E; Goldenberg I; McNitt S; Polonsky B; Aktas MK; Kutyifa V; Wazni OM; Zareba W; Goldenberg I
    Circulation; 2023 Jul; 148(3):241-252. PubMed ID: 37459413
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Are implantable cardioverter defibrillator shocks a surrogate for sudden cardiac death in patients with nonischemic cardiomyopathy?
    Ellenbogen KA; Levine JH; Berger RD; Daubert JP; Winters SL; Greenstein E; Shalaby A; Schaechter A; Subacius H; Kadish A;
    Circulation; 2006 Feb; 113(6):776-82. PubMed ID: 16461817
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prophylactic implantation of cardioverter defibrillators in idiopathic nonischemic cardiomyopathy for the primary prevention of death: a narrative review.
    Cevik C; Nugent K; Perez-Verdia A; Fish RD
    Clin Cardiol; 2010 May; 33(5):254-60. PubMed ID: 20513063
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Implantable Cardioverter Defibrillator for the Primary Prevention of Sudden Cardiac Death in Patients With Nonischemic Cardiomyopathy.
    Cavalcanti R; Aboul-Hosn N; Morales G; Abdel-Latif A
    Angiology; 2018 Apr; 69(4):297-302. PubMed ID: 28554215
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Arrhythmic burden among asymptomatic patients with ischemic cardiomyopathy and an implantable cardioverter-defibrillator.
    Sabbag A; Glikson M; Suleiman M; Boulos M; Goldenberg I; Beinart R; Nof E
    Heart Rhythm; 2019 Jun; 16(6):813-819. PubMed ID: 31153454
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical and Hospital Factors Affecting Treatment with Primary Prevention Implantable Cardioverter-Defibrillators in Ischemic Cardiomyopathy Patients.
    Lee JH; Yu HT; Oh IY; Choi EK; Sung JH; Lee YS; Kim JY; Baek Y; Park J; Joung B;
    Yonsei Med J; 2020 Nov; 61(11):942-950. PubMed ID: 33107237
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Association of Clustered Ventricular Arrhythmia and Cycle Length With Scar Burden in Cardiomyopathy.
    Vakil RM; Marine JE; Kolandaivelu A; Dickfeld T; Weiss RG; Tomaselli GF; Chrispin J; Wu KC
    JACC Clin Electrophysiol; 2022 Aug; 8(8):957-966. PubMed ID: 35981800
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characteristics of ventricular tachyarrhythmias and their susceptibility to antitachycardia pacing termination in patients with ischemic and nonischemic cardiomyopathy: A patient-level meta-analysis of three large clinical trials.
    Cheng A; Joung B; Brown ML; Koehler J; Lexcen DR; Sanders P; Ellenbogen KA
    J Cardiovasc Electrophysiol; 2020 Oct; 31(10):2720-2726. PubMed ID: 32700390
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Implantable cardioverter defibrillator therapy in patients with ischemic or non-ischemic cardiomyopathy and nonsustained ventricular tachycardia.
    Evonich RF; Maheshwari A; Gardiner JC; Khasnis A; Kantipudi S; Ip JH; Grimes D; Hayter G; Thakur RK
    J Interv Card Electrophysiol; 2004 Aug; 11(1):59-65. PubMed ID: 15273456
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical outcomes of implantable cardioverter-defibrillator therapy in noncompaction cardiomyopathy: a systematic review and meta-analysis.
    Tukker M; Schinkel AFL; Dereci A; Caliskan K
    Heart Fail Rev; 2023 Jan; 28(1):241-248. PubMed ID: 35689132
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.